Wagner SD - Search Results

1

Backbone resonance assignment of the BCL6-BTB/POZ domain.

Lin LY, Evans SE, Fairall L, Schwabe JWR, Wagner SD, Muskett FW. Lin LY, et al. Among authors: wagner sd. Biomol NMR Assign. 2018 Apr;12(1):47-50. doi: 10.1007/s12104-017-9778-z. Epub 2017 Sep 19. Biomol NMR Assign. 2018. PMID: 28929458 Free PMC article.

2

The ansamycin antibiotic, rifamycin SV, inhibits BCL6 transcriptional repression and forms a complex with the BCL6-BTB/POZ domain.

Evans SE, Goult BT, Fairall L, Jamieson AG, Ko Ferrigno P, Ford R, Schwabe JW, Wagner SD. Evans SE, et al. Among authors: wagner sd. PLoS One. 2014 Mar 4;9(3):e90889. doi: 10.1371/journal.pone.0090889. eCollection 2014. PLoS One. 2014. PMID: 24595451 Free PMC article.

3

GSK137, a potent small-molecule BCL6 inhibitor with in vivo activity, suppresses antibody responses in mice.

Pearce AC, Bamford MJ, Barber R, Bridges A, Convery MA, Demetriou C, Evans S, Gobbetti T, Hirst DJ, Holmes DS, Hutchinson JP, Jayne S, Lezina L, McCabe MT, Messenger C, Morley J, Musso MC, Scott-Stevens P, Manso AS, Schofield J, Slocombe T, Somers D, Walker AL, Wyce A, Zhang XP, Wagner SD. Pearce AC, et al. Among authors: wagner sd. J Biol Chem. 2021 Aug;297(2):100928. doi: 10.1016/j.jbc.2021.100928. Epub 2021 Jul 15. J Biol Chem. 2021. PMID: 34274316 Free PMC article.

4

Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma.

Beck D, Zobel J, Barber R, Evans S, Lezina L, Allchin RL, Blades M, Elliott R, Lord CJ, Ashworth A, Porter AC, Wagner SD. Beck D, et al. Among authors: wagner sd. J Biol Chem. 2016 Aug 5;291(32):16686-98. doi: 10.1074/jbc.M116.736868. Epub 2016 Jun 6. J Biol Chem. 2016. PMID: 27268052 Free PMC article.

5

The role of BCL6 in lymphomas and routes to therapy.

Wagner SD, Ahearne M, Ko Ferrigno P. Wagner SD, et al. Br J Haematol. 2011 Jan;152(1):3-12. doi: 10.1111/j.1365-2141.2010.08420.x. Epub 2010 Nov 18. Br J Haematol. 2011. PMID: 21083654 Free article. Review.

6

Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells.

Cortiguera MG, García-Gaipo L, Wagner SD, León J, Batlle-López A, Delgado MD. Cortiguera MG, et al. Among authors: wagner sd. Sci Rep. 2019 Nov 11;9(1):16495. doi: 10.1038/s41598-019-52714-4. Sci Rep. 2019. PMID: 31712669 Free PMC article.

7

Novel CTCF binding at a site in exon1A of BCL6 is associated with active histone marks and a transcriptionally active locus.

Batlle-López A, Cortiguera MG, Rosa-Garrido M, Blanco R, del Cerro E, Torrano V, Wagner SD, Delgado MD. Batlle-López A, et al. Among authors: wagner sd. Oncogene. 2015 Jan 8;34(2):246-56. doi: 10.1038/onc.2013.535. Epub 2013 Dec 23. Oncogene. 2015. PMID: 24362533 Free article.

8

A peptide aptamer to antagonize BCL-6 function.

Chattopadhyay A, Tate SA, Beswick RW, Wagner SD, Ko Ferrigno P. Chattopadhyay A, et al. Among authors: wagner sd. Oncogene. 2006 Apr 6;25(15):2223-33. doi: 10.1038/sj.onc.1209252. Oncogene. 2006. PMID: 16331266

9

ZEB1 and CtBP form a repressive complex at a distal promoter element of the BCL6 locus.

Papadopoulou V, Postigo A, Sánchez-Tilló E, Porter AC, Wagner SD. Papadopoulou V, et al. Among authors: wagner sd. Biochem J. 2010 Apr 14;427(3):541-50. doi: 10.1042/BJ20091578. Biochem J. 2010. PMID: 20175752

10

Post-transcriptional and post-translational regulation of Bcl2.

Willimott S, Wagner SD. Willimott S, et al. Among authors: wagner sd. Biochem Soc Trans. 2010 Dec;38(6):1571-5. doi: 10.1042/BST0381571. Biochem Soc Trans. 2010. PMID: 21118128 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

93 results

Search Page